Wandl UB - Search Results

1

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.

Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, Seeber S, Niederle N. Wandl UB, et al. Clin Immunol Immunopathol. 1992 Oct;65(1):70-4. doi: 10.1016/0090-1229(92)90250-r. Clin Immunol Immunopathol. 1992. PMID: 1382910

2

A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.

Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Becher R, Hirche H, Seeber S, Niederle N. Kloke O, et al. Eur J Haematol. 1992 Feb;48(2):93-8. doi: 10.1111/j.1600-0609.1992.tb00572.x. Eur J Haematol. 1992. PMID: 1547881 Clinical Trial.

3

Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy.

Opalka B, Wandl U, Beer U, Roggenbuck U, Kloke O, Niederle N. Opalka B, et al. Leukemia. 1991 Jun;5(6):452-6. Leukemia. 1991. PMID: 2056769

4

Treatment of chronic myelogenous leukemia with interferons alpha and gamma.

Kloke O, May D, Wandl U, Becher R, Opalka B, Beer U, Niederle N. Kloke O, et al. Blut. 1990 Jul;61(1):45-6. doi: 10.1007/BF01739433. Blut. 1990. PMID: 2117476

5

Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.

Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, Hawig I, Opalka B, Seeber S, Becher R. Kloke O, et al. Br J Haematol. 1993 Mar;83(3):399-403. doi: 10.1111/j.1365-2141.1993.tb04663.x. Br J Haematol. 1993. PMID: 8485045

6

Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.

Wandl UB, Kloke O, Nagel-Hiemke M, Moritz T, Becher R, Opalka B, Holtkamp W, Bartels H, Seeber S, Niederle N. Wandl UB, et al. Br J Haematol. 1992 Aug;81(4):516-9. doi: 10.1111/j.1365-2141.1992.tb02984.x. Br J Haematol. 1992. PMID: 1390238

7

Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical data.

Moritz T, Kloke O, Nagel-Hiemke M, Kummer G, Wandl UB, Opalka B, Plappert B, Kempeni J, Seeber S, Niederle N. Moritz T, et al. Among authors: wandl ub. Cancer Immunol Immunother. 1992;35(5):342-6. doi: 10.1007/BF01741148. Cancer Immunol Immunother. 1992. PMID: 1394338 Free PMC article. Clinical Trial.

8

No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CML.

Opalka B, Wandl UB, Kloke O, Beer U, Seeber S, Niederle N. Opalka B, et al. Among authors: wandl ub. Leuk Res. 1992 Sep;16(9):937-9. doi: 10.1016/0145-2126(92)90039-a. Leuk Res. 1992. PMID: 1405723

9

Clonogenic assay is not predictive but reflects therapeutic efficacy of interferons in the treatment of chronic myelogenous leukemia.

Wandl UB, Niederle N, Kranzhoff M, Seeber S. Wandl UB, et al. Int J Cell Cloning. 1992 Sep;10(5):292-8. doi: 10.1002/stem.5530100507. Int J Cell Cloning. 1992. PMID: 1453016 Free article.

10

Treatment of chronic myelogenous leukemia with different cytokines.

Wandl UB, Opalka B, Kloke O, Nagel-Hiemke M, Moritz T, Niederle N. Wandl UB, et al. Semin Oncol. 1992 Apr;19(2 Suppl 4):88-94. Semin Oncol. 1992. PMID: 1553580 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters